• EN - English
  • NL - Nederlands
Parliamentary question - E-001490/2022(ASW)Parliamentary question

Answer given by Mr Breton on behalf of the European Commission

Regulation (EC) No 1223/2009 on Cosmetic Products (CPR)[1] ensures a high level of protection of human health and the functioning of the internal market for cosmetics.

It lays down a system of restrictions and prohibition on the use of certain substances in cosmetics. Concerns with regard to endocrine disruptors (EDCs) are addressed via the risk assessment carried out by the Scientific Committee on Consumer Safety.

The 2018 Commission report on EDCs[2] concluded that the CPR provides adequate tools to regulate the use of substances that present a potential risk for human health. In addition, the Commission is in the process of regulating additional fragrance allergens, as well as EDCs.

Still, the Chemicals Strategy for Sustainability[3] recognises the need for a targeted revision of the CPR. The Commission published an inception impact assessment[4] presenting the problems it intends to address to achieve the CPR objectives .

This includes the prohibition of EDCs that are unsafe for use in cosmetic products, the application of a mixture assessment factor to account for the cocktail effects, and the introduction of digital labelling to enhance transparency and improve communication of information to consumers.

The Commission intends to submit a legal proposal to the Parliament and the Council by the end of 2022.

Last updated: 13 June 2022
Legal notice - Privacy policy